Skip to main content
. 2018 Feb 13;23(4):634–640. doi: 10.1007/s10147-018-1250-2

Fig. 4.

Fig. 4

Relationship between adverse events (AEs) and progression-free survival (PFS). a Median PFS of patients with immune-related AEs was 4.4 months, whereas that of patients without immune-related AEs was 2.1 months (p = 0.0516). b Median PFS of patients with AEs was 2.1 months, whereas that of patients without AEs was 3.4 months (p = 0.665)